Advances in Therapy

, 20:50 | Cite as

Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: A literature review

  • Kjeld Hermansen
  • Bo Dinesen
  • Lars H. Hoie
  • Eve Morgenstern
  • Joerg Gruenwald


Abnormal lipid levels contribute significantly to the risk of coronary heart disease, a major cardiovascular disease and a serious health problem. Various dietary and pharmacologic treatments have been devised to reduce elevated blood cholesterol levels. Soy protein, soluble fiber, and plant sterol/ester-containing margarines are promising new food-component candidates that may help to realize this goal. Of particular interest in this context is the LDL:HDL ratio, a strong predictor of cardiac events. This report is a review of more than 50 recent trials to determine how such dietary components and garlic affect the LDL:HDL ratio and other lipid parameters. Consumption of new soy products containing high, fixed levels of isoflavones, cotyledon soy fiber, and soy phospholipids (Abacor® and Abalon®) significantly reduced the LDL:HDL ratio by up to 27%. Soluble dietary fibers such as psyllium and beta glucan from oat bran had a variable effect on LDL-cholesterol levels in the studies analyzed. Plant sterol esters, when consumed in margarines, lowered the LDL:HDL ratio by up to 22%. On average, Abacor and Abalon reduced the LDL:HDL ratio by 20%, LDL cholesterol by 15%, total cholesterol by 10%, and triglycerides by 6%, and increased HDL cholesterol by 5%. The new soy-based supplements may therefore play a valuable role in reducing cardiovascular risk.


hypercholesterolemia soy protein beta glucan phytosterol dietary fiber lipid lowering cardiovascular disease 


  1. 1.
    Isles CG, Paterson JR. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.Q J Med. 2000;93:567–574.Google Scholar
  2. 2.
    Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity.JAMA. 2000;284:311–318.PubMedCrossRefGoogle Scholar
  3. 3.
    American Heart Association.2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000:1–22.Google Scholar
  4. 4.
    Food and Drug Administration. Food labeling: health claims; oats and coronary heart disease; final rule (21 CFR part 101).Federal Register. January 23, 1997:3583–3601.Google Scholar
  5. 5.
    Food and Drug Administration. Food labeling: health claims; soluble fiber from certain foods and coronary heart disease; final rule (21 CFR part 101).Federal Register. February 18, 1998:8103–8121.Google Scholar
  6. 6.
    Food and Drug Administration. Food labeling: health claims; plant sterol/stanol esters and coronary heart disease; interim final rule (21 CFR part 101).Federal Register. September 8, 2000: 54686–54739.Google Scholar
  7. 7.
    Food and Drug Administration. Food labeling: health claims; soy protein; interim final rule (21 CFR part 101.82).Federal Register. October 26, 1999:57700–57733.Google Scholar
  8. 8.
    Marsland C. A soy tutorial.Nutritional World. 2000;96–101.Google Scholar
  9. 9.
    Young VR. Soy protein in relation to human protein and amino acid nutrition.J Am Diet Assoc. 1991;91:828–835.PubMedGoogle Scholar
  10. 10.
    Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids.N Engl J Med. 1995;333:276–282.PubMedCrossRefGoogle Scholar
  11. 11.
    Puska P, Korpelainen V, Hoie LH, Skovlund E, Lahti T, Smerud KT. Soy in hypercholesterolaemia: a double-blind, placebo-controlled trial.Eur J Clin Nutr. 2002;56:352–357.PubMedCrossRefGoogle Scholar
  12. 12.
    Puska P, Korpelainen V, Hoie LH, Skovlund E, Smerud KT. Soy-fibre yogurt improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial. In press.Google Scholar
  13. 13.
    Tonstad S, Hoie L, Smerud KT. Effects of 2 doses of soy protein versus casein on serum lipids and lipoproteins and plasma total homocysteine in hypercholesterolemic subjects.Am J Clin Nutr. 2002;76:78–84.PubMedGoogle Scholar
  14. 14.
    Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular disease risk markers in type 2 diabetic subjects.Diabetes Care. 2001;24:228–233.PubMedCrossRefGoogle Scholar
  15. 15.
    Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman JW, Hasler CM. Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholes-terolemic men.Am J Clin Nutr. 2000;71:1077–1084.PubMedGoogle Scholar
  16. 16.
    Baum JA, Teng H, Erdman JW, et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women.Am J Clin Nutr. 1998;68:545–551.PubMedGoogle Scholar
  17. 17.
    Crouse JR, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins.Arch Intern Med. 1999;159:2070–2076.PubMedCrossRefGoogle Scholar
  18. 18.
    Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women.Menopause. 1999;6:7–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Wong WW, Smith EO, Stuff JE, Hachey DL, Heird WC, Pownell HJ. Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men.Am J Clin Nutr. 1998;68:1385S-1389S.PubMedGoogle Scholar
  20. 20.
    Merz-Demlow BE, Duncan AM, Wangen KE, et al. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women.Am J Clin Nutr. 2000;71:1462–1469.PubMedGoogle Scholar
  21. 21.
    Wangen KE, Duncan AM, Xu X, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women.Am J Clin Nutr. 2001;73:225–231.PubMedGoogle Scholar
  22. 22.
    Ashton E, Ball M. Effects of soy as tofu vs meat on lipoprotein concentrations.Eur J Clin Nutr. 2000;54:14–19.PubMedCrossRefGoogle Scholar
  23. 23.
    Kurowska EM, Jordan J, Spence JD, et al. Effects of substituting dietary soybean protein and oil for milk protein and fat in subjects with hypercholesterolemia.Clin Invest Med. 1997;20:162–170.PubMedGoogle Scholar
  24. 24.
    Brown L, Rosner B, Willet WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis.Am J Clin Nutr. 1999;69:30–42.PubMedGoogle Scholar
  25. 25.
    Nordgaard I, Hove H, Clausen MR, Mortensen PB. Colonic production of butyrate in patients with previous colonic cancer during long-term treatment with dietary fibre (Plantago ovata seeds).Scand J Gastroenterol. 1996;31:1011–1020.PubMedCrossRefGoogle Scholar
  26. 26.
    Lia A, Andersson H, Mekki N, Juhel C, Senft M, Lairon D. Postprandial lipemia in relation to sterol and fat excretion in ileostomy subjects given oat-bran and wheat test meals.Am J Clin Nutr. 1997;66:357–365.PubMedGoogle Scholar
  27. 27.
    Hendler SS, Rorvik MS, Fleming T, Deutsch M, Wyble C, eds. Psyllium. In:PDR® for Nutritional Supplements. Montvale, NJ: Thomson Healthcare; 2001:384–386.Google Scholar
  28. 28.
    Anderson JW, Allgood LD, Lawrence A, Altringer LA, Jerdack GR, Hengehold DA. Cholesterollowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials.Am J Clin Nutr. 2000;71:472–479.PubMedGoogle Scholar
  29. 29.
    Davidson MH, Maki KC, Kong JC, et al. Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia.Am J Clin Nutr. 1998;67:367–376.PubMedGoogle Scholar
  30. 30.
    Anderson JW, Davidson MH, Blonde L, et al. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia.Am J Clin Nutr. 2000;71:1433–1438.PubMedGoogle Scholar
  31. 31.
    MacMahon M, Carless J. Ispaghula husk in the treatment of hypercholesterolaemia: a double-blind controlled study.J Cardiovasc Risk. 1998;5:167–172.PubMedCrossRefGoogle Scholar
  32. 32.
    Rodriguez-Morán M, Guerrero-Romero F, Lazcano-Burciaga G. Lipid- and glucose-lowering efficacy of plantago psyllium in type II diabetes.J Diabetes Complications. 1998;12:273–278.PubMedCrossRefGoogle Scholar
  33. 33.
    Romero AL, Romero JE, Galaviz S, Fernandez ML. Cookies enriched with psyllium or oat bran lower plasma LDL cholesterol in normal and hypercholesterolemic men from northern Mexico.JAm Coll Nutr. 1998;17:601–608.Google Scholar
  34. 34.
    Gerhardt AL, Gallo NB. Full-fat rice bran and oat bran similarly reduce hypercholesterolemia in humans.J Nutr. 1998;128:865–869.PubMedGoogle Scholar
  35. 35.
    Behall KM, Scholfield DJ, Hallfrisch J. Effect of beta-glucan level in oat fiber extracts on blood lipids in men and women.J Am Coll Nutr. 1997;16:46–51.PubMedGoogle Scholar
  36. 36.
    Önning G, Wallmark A, Persson M, Akesson B, Elmstahl S, Öste R. Consumption of oat milk for 5 weeks lowers serum cholesterol and LDL cholesterol in free-living men with moderate hypercholesterolemia.Ann Nutr Metab. 1999;43:301–309.PubMedCrossRefGoogle Scholar
  37. 37.
    Lovegrove JA, Clohessy A, Milon H, Williams CM. Modest doses of β-glucan do not reduce concentrations of potentially atherogenic lipoproteins.Am J Clin Nutr. 2000;72:49–55.PubMedGoogle Scholar
  38. 38.
    Beer MU, Arrigoni E, Amadò R. Effects of oat gum on blood cholesterol levels in healthy young men.Eur J Clin Nutr. 1995;49:517–522.PubMedGoogle Scholar
  39. 39.
    Pick ME, Hawrysh ZJ, Gee MI, Toth E, Garg ML, Hardin RT. Oat bran concentrate bread products improve long-term control of diabetes: a pilot study.J Am Diet Assoc. 1996;96:1254–1261.PubMedCrossRefGoogle Scholar
  40. 40.
    Plat J, Mensink RP. Vegetable oil based versus wood based stanol ester mixtures: effects on serum lipids and hemostatic factors in non-hypercholesterolemic subjects.Atherosclerosis. 2000;148:101–112.PubMedCrossRefGoogle Scholar
  41. 41.
    Ling WH, Jones PJH. Minireview. Dietary phytosterols: a review of metabolism, benefits and side effects.Life Sci. 1995;57:195–206.PubMedCrossRefGoogle Scholar
  42. 42.
    Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population.N Engl J Med. 1995;333:1308–1312.PubMedCrossRefGoogle Scholar
  43. 43.
    Miettinen TA, Vuoristo M, Nissinen M, Järvinen HJ, Gylling H. Serum, biliary, and fecal cholesterol and plant sterols in colectomized patients before and during consumption of stanol ester margarine.Am J Clin Nutr. 2000;71:1095–1102.PubMedGoogle Scholar
  44. 44.
    Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.Am J Cardiol. 2000;86:46–52.PubMedCrossRefGoogle Scholar
  45. 45.
    Hallikainen MA, Uusitupa MIJ. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects.Am J Clin Nutr. 1999;69:403–410.PubMedGoogle Scholar
  46. 46.
    Hallikainen MA, Sarkkinen ES, Uusitupa MIJ. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner.J Nutr. 2000;130:767–776.PubMedGoogle Scholar
  47. 47.
    Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake.Metabolism. 1999;48:575–580.PubMedCrossRefGoogle Scholar
  48. 48.
    Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects.Eur J Clin Nutr. 1998;52:334–343.PubMedCrossRefGoogle Scholar
  49. 49.
    Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters.J Lipid Res. 2000;41:697–705.PubMedGoogle Scholar
  50. 50.
    Jones PJH, Ntanios FY, Raeini-Sarjaz M, Vanstone CA. Cholesterol-lowering efficacy of a sitostanolcontaining phytosterol mixture with a prudent diet in hyperlipidemic men.Am J Clin Nutr. 1999;69:1144–1150.PubMedGoogle Scholar
  51. 51.
    Denke MA. Lack of efficacy of low-dose sitostanol therapy as an adjunct to a cholesterol-lowering diet in men with moderate hypercholesterolemia.Am J Clin Nutr. 1995;61:392–396.PubMedGoogle Scholar
  52. 52.
    Hendriks HFJ, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects.Eur J Clin Nutr. 1999;53:319–327.PubMedCrossRefGoogle Scholar
  53. 53.
    Ayesh R, Weststrate A, Drewitt PN, Hepburn PA. Safety evaluation of phytosterol esters, Part 5: faecal short-chain fatty acid and microflora content, faecal bacterial enzyme activity and serum female sex hormones in healthy normolipidaemic volunteers consuming a controlled diet either with or without a phytosterol ester-enriched margarine.Food Chem Toxicol. 1999;37:1127–1138.PubMedCrossRefGoogle Scholar
  54. 54.
    Silagy C, Neil A. Garlic as a lipid lowering agent—a meta-analysis.J R Coll Physicians Lond. 1994;28:2–8.Google Scholar
  55. 55.
    Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol.Ann Intern Med. 1993;119:599–605.PubMedGoogle Scholar
  56. 56.
    Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials.Ann Intern Med. 2000;133:420–429.PubMedGoogle Scholar
  57. 57.
    Neil HAW, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-analysis.J R Coll Physicians Lond. 1996;30:329–334.PubMedGoogle Scholar
  58. 58.
    Simons LA, Balasubramaniam S, Königsmark M, Parfitt A, Simons J, Peters W. On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolaemia.Atherosclerosis. 1995;113:219–225.PubMedCrossRefGoogle Scholar
  59. 59.
    Bordia A, Verma SK, Srivastava KC. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease.Prostaglandins, Leukot Essent Fatty Acids. 1998;58:257–263.CrossRefGoogle Scholar
  60. 60.
    Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies.J Nutr. 2001;131:989S-993S.PubMedGoogle Scholar
  61. 61.
    Gardner CD, Chatterjee LM, Carlson JJ. The effect of a garlic preparation on plasma lipid levels in moderately hypercholesterolemic adults.Atherosclerosis. 2001;154:213–220.PubMedCrossRefGoogle Scholar
  62. 62.
    Superko HR, Krauss RM. Garlic powder: effect on plasma lipids, postprandial lipemia, lowdensity lipoprotein particle size, high-density lipoprotein subclass distribution and lipoprotein (a).JAm Coll Cardiol. 2000;35:321–326.CrossRefGoogle Scholar
  63. 63.
    Lash JP, Cardoso LR, Mesler PM, Walczak DA, Pollak R. The effect of garlic on hypercholesterolemia in renal transplant patients.Transplant Proc. 1998;30:189–191.PubMedCrossRefGoogle Scholar
  64. 64.
    Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins. A multicenter, randomized, placebo-controlled trial.Arch Intern Med. 1998;158:1189–1194.PubMedCrossRefGoogle Scholar
  65. 65.
    Hendler SS, Rorvik MS, Fleming T, Deutsch M, Wyble C, eds. Soy isoflavones, soy proteins. In:PDR®for Nutritional Supplements. Montvale, NJ: Thomson Healthcare; 2001:428–431.Google Scholar
  66. 66.
    Olson BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a metaanalysis.J Nutr. 1997;127:1973–1980.PubMedGoogle Scholar
  67. 67.
    Wood PJ, Beer MU. Functional oat products. In: Mazza G, ed.Functional Foods. Basel: Technomic; 1998:1–37.Google Scholar
  68. 68.
    Lo GS, Goldberg AP, Lim A, Grundhauser JJ, Anderson C, Schonfeld G. Soy fiber improves lipid and carbohydrate metabolism in primary hyperlipidemic subjects.Atherosclerosis. 1986;62:239–248.PubMedCrossRefGoogle Scholar
  69. 69.
    Anderson JW, Deakins DA, Floore TL, Smith BM, Whitis SE. Dietary fiber and coronary heart disease.Crit Rev Food Sci Nutr. 1990;29:95–147.PubMedCrossRefGoogle Scholar
  70. 70.
    Miettinen TA. Stanol esters in treatment of hypercholesterolaemia.Eur Heart J Suppl. 1999;1(suppl S):S50-S57.Google Scholar
  71. 71.
    Spigelski D, Jones PJH. Efficacy of garlic supplementation in lowering serum cholesterol levels.Nutr Rev. 2001;59:236–244.PubMedGoogle Scholar

Copyright information

© Health Communications Inc 2003

Authors and Affiliations

  • Kjeld Hermansen
    • 1
  • Bo Dinesen
    • 2
  • Lars H. Hoie
    • 2
  • Eve Morgenstern
    • 3
  • Joerg Gruenwald
    • 3
  1. 1.Department of Endocrinology and MetabolismAarhus University HospitalAarhusDenmark
  2. 2.Nutri Pharma ASACopenhagenDenmark
  3. 3.Nutri Pharma GmbHBerlinGermany

Personalised recommendations